ADAM17 Aggravates the Inflammatory Response by Modulating Microglia Polarization Through the TGF-β1/Smad Pathway Following Experimental Traumatic Brain Injury.


Journal

Journal of neurotrauma
ISSN: 1557-9042
Titre abrégé: J Neurotrauma
Pays: United States
ID NLM: 8811626

Informations de publication

Date de publication:
07 2023
Historique:
medline: 7 7 2023
pubmed: 9 4 2023
entrez: 8 4 2023
Statut: ppublish

Résumé

Microglia-mediated neuroinflammatory responses play important roles in secondary neurological injury after traumatic brain injury (TBI). The TGF-β pathway participates in the regulation of M1/M2 phenotype transformation of microglia. TGF-β can activate the Smad pathway by binding to TGF-βRs, which is regulated by the cleavage function of A disintegrin and metalloproteinase 17 (ADAM17). However, the role of ADAM17 and the associated signaling pathways in the pathological process after TBI remain unclear. Herein, we assessed the transformation of microglia M1/M2 phenotype polarization and the neuroinflammatory response after the inhibition of ADAM17. The formation of TGF-βRs and TGF-β1/TGF-βRII complexes on microglia were detected to evaluate the effect of ADAM17 inhibition on the TGF-β1/Smad pathway. ADAM17 was highly expressed after TBI and mainly located in the microglia. the inhibition of ADAM17 improved neurological function after TBI. The neuroprotective effect of ADAM17 inhibition was related to a shift from the M1 microglial phenotype to the M2 microglial phenotype, thus reducing TBI-induced neuroinflammation. ADAM17 inhibition increased expression of TGF-βRs on the microglia membrane, promoted formation of TGF-β1/TGF-βRII complexes, and induced intranuclear translocation of Smads, which activated the TGF-β/Smad pathway. In conclusion, our study suggested that ADAM17 inhibition regulated microglia M1/M2 phenotype polarization through the TGF-β1/Smad pathway and influenced the neuroinflammatory response after TBI.

Identifiants

pubmed: 37029898
doi: 10.1089/neu.2022.0373
doi:

Substances chimiques

ADAM17 Protein EC 3.4.24.86
ADAM17 protein, human EC 3.4.24.86
Transforming Growth Factor beta1 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1495-1509

Auteurs

Xiangrong Chen (X)

Department of Neurosurgery, Fuzong Clinical Medical College, Fujian Medical University, Fuzhou, China.
Fujian Institutes of Brain Disorders and Brain Science, Fuzong Clinical Medical College, Fujian Medical University, Fuzhou, China.
Department of Neurosurgery, National Regional Medical Center, First Affiliated Hospital, Fuzong Clinical Medical College, Fujian Medical University, Fuzhou, China.
Department of Neurosurgery, the Second Clinical Medical College, the Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China.

Jieran Yao (J)

Department of Neurosurgery, the Second Clinical Medical College, the Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China.
Department of Anesthesiology and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.

Jinqing Lai (J)

Department of Neurosurgery, the Second Clinical Medical College, the Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China.

Long Lin (L)

Department of Neurosurgery, Fuzong Clinical Medical College, Fujian Medical University, Fuzhou, China.

Yue Chen (Y)

Department of Neurosurgery, Fuzong Clinical Medical College, Fujian Medical University, Fuzhou, China.
Department of Neurosurgery, National Regional Medical Center, First Affiliated Hospital, Fuzong Clinical Medical College, Fujian Medical University, Fuzhou, China.

Yuanxiang Lin (Y)

Department of Neurosurgery, Fuzong Clinical Medical College, Fujian Medical University, Fuzhou, China.
Department of Neurosurgery, National Regional Medical Center, First Affiliated Hospital, Fuzong Clinical Medical College, Fujian Medical University, Fuzhou, China.

Wenhua Fang (W)

Department of Neurosurgery, Fuzong Clinical Medical College, Fujian Medical University, Fuzhou, China.
Department of Neurosurgery, National Regional Medical Center, First Affiliated Hospital, Fuzong Clinical Medical College, Fujian Medical University, Fuzhou, China.

Chenyu Ding (C)

Department of Neurosurgery, Fuzong Clinical Medical College, Fujian Medical University, Fuzhou, China.
Department of Neurosurgery, National Regional Medical Center, First Affiliated Hospital, Fuzong Clinical Medical College, Fujian Medical University, Fuzhou, China.

Dezhi Kang (D)

Department of Neurosurgery, Fuzong Clinical Medical College, Fujian Medical University, Fuzhou, China.
Department of Neurosurgery, National Regional Medical Center, First Affiliated Hospital, Fuzong Clinical Medical College, Fujian Medical University, Fuzhou, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH